A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Bladder cancer; Bone metastases; Cancer metastases; Liver metastases; Lung cancer; Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms GETUG-AFU 26 NIVOREN; NIVOREN GETUG-AFU 26

24 Oct 2023 Results (n=353) of analysis assessing baseline cytokine concentrations according to the line of treatment and investigate their additional prognostic value presented at the 48th European Society for Medical Oncology Congress
06 Jun 2023 Results (n=212) assessing prognostic impact of MAdCAM-1 in ICI-treated mRCC patients presented at the 59th Annual Meeting of the American Society of Clinical Oncology
18 Feb 2023 Results from translational NIVOREN GETUG-AFU 26 study presented at the 2023 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com